[Vitreous metastasis of malignant cutaneous melanoma during treatment with ipilimumab].
An isolated metastasis of the vitreous body from a malignant cutaneous melanoma without involvement of the choroid is an extremely rare occurrence. We report on the case of a 59-year-old female patient who presented with a vitreous body metastasis during systemic treatment with the anti-cytotoxic T lymphocyte-associated antigen (anti-CTLA 4) antibody ipilimumab. This case report underlines the diagnostic difficulties in such cases and points out the risk of metastasis in immune-privileged sites under systemic immunotherapy.
Klinikum rechts der Isar, Augenklinik der TU München, 81675, München, Deutschland. Niklas.Kellermann@mri.tum.de.
N
N
Kellermann
Klinikum rechts der Isar, Augenklinik der TU München, 81675, München, Deutschland.
M
M
Maier
Klinikum rechts der Isar, Augenklinik der TU München, 81675, München, Deutschland.
N
N
Feucht
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005134:Eye Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000556:secondary*; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma / Q000139:chemically induced* / Q000473:pathology*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014822:Vitreous Body / Q000187:drug effects / Q000473:pathology*
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab
Ipilimumab; Malignant melanoma; Vitrectomy; Vitreous body; Vitreous metastasis